Evidence supporting the use of: Serratiopeptidase
For the health condition: Anal Fistula or Fissure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Serratiopeptidase is a proteolytic enzyme originally derived from the bacterium Serratia marcescens. Its use in the management of anal fistula and fissure is primarily based on its anti-inflammatory and anti-edematous properties. Scientific studies suggest that serratiopeptidase can reduce inflammation and swelling by breaking down inflammatory mediators and fibrin, thus potentially aiding in faster healing of soft tissue injuries and reducing postoperative pain and edema. This mechanism provides a rationale for its use as an adjunct treatment in perianal conditions such as fissures and fistulas, where inflammation, edema, and pain are prominent symptoms.

However, the direct evidence supporting serratiopeptidase specifically for anal fistula or fissure is limited. Most clinical trials and systematic reviews focus on its benefits in dental surgery, trauma, or general postoperative swelling rather than anorectal disorders. Some small-scale studies and anecdotal reports in proctology suggest that patients may experience symptom relief, but these studies are often underpowered or lack rigorous controls. No large, high-quality randomized controlled trials have firmly established its efficacy for anal fistula or fissure. Its use in this context is therefore based on extrapolation from its general anti-inflammatory effects rather than robust direct evidence.

In summary, while there is a plausible scientific basis for using serratiopeptidase to support healing and symptom relief in anal fissure and fistula, the specific evidence is weak (rated 2/5), and more targeted clinical research is needed to validate its use for these conditions.

More about serratiopeptidase
More about Anal Fistula or Fissure